Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

Natera Inc. (NASDAQ:NTRA) is one of the best growth stocks to buy now. On September 30, Natera announced the publication of a validation study for its personalized molecular residual disease test, Signatera, in the Journal of Clinical Oncology – Precision Oncology/JCO PO. The peer-reviewed manuscript features results from the largest-ever ctDNA study in testicular cancer and showed that Signatera outperformed standard-of-care serum tumor markers/STMs in prognostic evaluation.

The multicenter, retrospective study evaluated circulating tumor DNA/ctDNA as a prognostic biomarker for patients with germ cell tumors/GCTs, specifically testicular cancer, which accounts for ~95% of all GCTs and is the most common malignancy in men aged 15-35. The study analyzed 324 plasma samples from 74 patients with testicular cancer across stages I-III.

Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer

Signatera was used to assess ctDNA levels before, during, and after treatment to determine its association with event-free survival. Testicular cancer management is often complicated by the limited utility of conventional STMs, which can lead to unnecessary chemotherapy. Findings showed that Signatera-positivity was significantly associated with shorter EFS, highlighting its unique value to reliably detect molecular residual disease and predict clinical outcomes.

Natera Inc. (NASDAQ:NTRA) is a diagnostics company that provides molecular testing services worldwide. It serves independent laboratories, national & regional reference laboratories, medical centers & physician practices, research laboratories, and pharmaceutical companies.

While we acknowledge the potential of NTRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NTRA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.